The management of newly diagnosed prostate cancer is challenging because of its heterogeneity in histology, genetics and clinical outcome. The clinical outcome of patients with Gleason score 7 prostate cancer varies greatly. Improving risk assessment in this group is of particular interest, as Gleason score 7 prostate cancer on biopsy is an important clinical threshold for active treatment. Architecturally, four Gleason grade 4 growth patterns are recognized: ill-formed, fused, glomeruloid and cribriform. The aim of this review is to describe the role of cribriform growth in prostate cancer with respect to diagnosis, prognosis and molecular pathology. Secondly, we will discuss clinical applications for cribriform prostate cancer and give recommendations for future research.

Additional Metadata
Keywords Cancer, Cribriform, Pathology, Prostate
Persistent URL dx.doi.org/10.21037/tau.2017.12.33, hdl.handle.net/1765/104275
Journal Translational Andrology and Urology
Rights no subscription
Citation
Kweldam, C.F, van der Kwast, Th.H, & Leenders, G.J.H.L. (2018). On cribriform prostate cancer. Translational Andrology and Urology, 7(1), 145–154. doi:10.21037/tau.2017.12.33